AMADEUS (N=79)	OAK (N=344)	POPLAR (N=81)	P-value
Sex
F	36 (45.6%)	125 (36.3%)	25 (30.9%)	0.145
M	43 (54.4%)	219 (63.7%)	56 (69.1%)
Tumor.type
AMPV	1 (1.3%)	0 (0%)	0 (0%)	<0.001
BRCA	3 (3.8%)	0 (0%)	0 (0%)
CRCA	7 (8.9%)	0 (0%)	0 (0%)
CRPC	12 (15.2%)	0 (0%)	0 (0%)
CVXC	2 (2.5%)	0 (0%)	0 (0%)
GEJC	1 (1.3%)	0 (0%)	0 (0%)
GSCA	2 (2.5%)	0 (0%)	0 (0%)
HCCA	1 (1.3%)	0 (0%)	0 (0%)
HECH	3 (3.8%)	0 (0%)	0 (0%)
HNCA	9 (11.4%)	0 (0%)	0 (0%)
LUCA	2 (2.5%)	0 (0%)	0 (0%)
NESK	1 (1.3%)	0 (0%)	0 (0%)
NEUC	3 (3.8%)	0 (0%)	0 (0%)
NSCLC	0 (0%)	344 (100%)	81 (100%)
OVCA	6 (7.6%)	0 (0%)	0 (0%)
PANC	2 (2.5%)	0 (0%)	0 (0%)
PELV	2 (2.5%)	0 (0%)	0 (0%)
PENC	1 (1.3%)	0 (0%)	0 (0%)
PRTC	2 (2.5%)	0 (0%)	0 (0%)
RNCA	3 (3.8%)	0 (0%)	0 (0%)
SARC	7 (8.9%)	0 (0%)	0 (0%)
TERA	1 (1.3%)	0 (0%)	0 (0%)
THYR	3 (3.8%)	0 (0%)	0 (0%)
URET	1 (1.3%)	0 (0%)	0 (0%)
UTCA	4 (5.1%)	0 (0%)	0 (0%)
Treatment
atezo	0 (0%)	0 (0%)	81 (100%)	<0.001
MPDL3280A	0 (0%)	344 (100%)	0 (0%)
Nivolumab	7 (8.9%)	0 (0%)	0 (0%)
Nivolumab + Ipilimumab	72 (91.1%)	0 (0%)	0 (0%)
PFS
Mean (SD)	5.54 (7.59)	5.43 (6.77)	5.90 (6.10)	<0.001
Median [Min, Max]	2.07 [0.0329, 41.9]	2.53 [0.0329, 30.5]	2.83 [0.263, 23.3]
PFS.status
0	16 (20.3%)	30 (8.7%)	7 (8.6%)	0.009
1	63 (79.7%)	314 (91.3%)	74 (91.4%)
OS
Mean (SD)	12.3 (11.5)	13.1 (9.43)	13.3 (7.31)	0.01
Median [Min, Max]	7.92 [0.164, 42.9]	10.8 [0.296, 33.4]	12.6 [1.02, 24.3]
OS.status
0	36 (45.6%)	107 (31.1%)	30 (37.0%)	0.043
1	43 (54.4%)	237 (68.9%)	51 (63.0%)